Abstract
Little is known regarding COVID-19 vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through the end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) super-region. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, White race, male sex, BMI, and higher burden of cardiovascular risk.